© 2011, Crown Copyright.
Included under terms of UK Non-commercial Government License.
Bookshelf ID: NBK100732
< PrevNext >
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
< PrevNext >
Growth Monitoring for Short Stature: Update of a Systematic Review and Economic Model
Health Technology Assessment, No. 15.11
D Craig, D Fayter, L Stirk, and R Crott.
Author Information and AffiliationsSouthampton (UK): NIHR Journals Library; 2011 Feb.
Abstract
Objectives:
The aim of the project was to compare different screening rules and/or referral cut-offs for the identification of children with disorders of short stature. We undertook an update of a previous systematic review and economic model that addressed the same question.
Data sources:
Sources searched included MEDLINE, EMBASE, Science Citation Index, Social Science Citation Index, Conference Proceedings Citation Index – Science/Social Science & Humanities, Cochrane Library 2009 Issue 4, Office of Health Economics Health Economic Evaluations Database, and the NHS Economic Evaluation Database.
Review methods:
The review was conducted as an update to our previous assessment in 2007. Searching covered January 2005 to November 2009 with no language or publication restrictions. Two reviewers examined full papers for relevance. Data extraction was conducted by one reviewer and independently checked by a second. In addition, searches were conducted to identify quality of life or utility papers to inform the economic evaluation. We developed a probabilistic decision analytic model to estimate the costs and quality-adjusted life-year (QALY) gains from the perspective of the UK NHS and personal social services. The model was a cohort model, assuming a homogeneous population of 5-year-olds at baseline.
Results:
One study was included in the systematic review. The study was not UK based, but had been identified in the brief as relevant to the UK setting. The study's authors examined the performance of a number of rules to determine sensitivity and specificity of referral for short stature in four patient groups and three reference groups in the Netherlands. They derived an algorithm for referral based on the optimal rules. No new studies were located that provided appropriate quality of life or utilities data for the economic model. The model was based on the previous assessment which was updated to better reflect current UK clinical practice. We compared two alternative monitoring strategies, one of which was based on the study identified in our systematic review (Grote strategy); the other was based on UK consensus (UK strategy). We identified that the UK strategy was the least effective and least costly, with a mean gain of 0.001 QALYs at a mean cost of £21. The Grote strategy was both more expensive and more effective, with a mean cost of £68 and a mean QALY gain of 0.042. The incremental cost-effectiveness ratio was £1144 per QALY gained.
Conclusions:
This assessment contributes further knowledge, but does not provide definitive answers on how to deliver growth monitoring. In particular, we were unable to ascertain current practice in the UK for growth screening. Further, we were unable to evaluate through the use of identified studies and modelling an optimal referral cut-off and age at which to screen. We identified a number of research questions that would further inform referral strategies, which in summary would involve further primary and secondary data collection.
Funding:
The National Institute for Health Research Health Technology Assessment programme.
Contents
- NIHR Health Technology Assessment programme
- Glossary
- List of abbreviations
- Executive summary
- 1. General background
- 2. Aims and objectives
- 3. Methods
- 4. Results
- 5. Discussion
- 6. Conclusions
- Acknowledgements
- References
- Appendix 1 Search strategy
- Appendix 2 Studies excluded from the systematic review of referral
- Appendix 3 Studies identified in the quality of life and utilities literature search
- Appendix 4 Included study data extraction
- Health Technology Assessment programme
Suggested citation:
Craig D, Fayter D, Stirk L, Crott R. Growth monitoring for short stature: update of a systematic review and economic model. Health Technol Assess 2011;15(11).
Declared competing interests of authors: none
The research reported in this issue of the journal was commissioned by the HTA programme as project number 09/52/01. The contractual start date was in February 2010. The draft report began editorial review in April 2010 and was accepted for publication in September 2010. As the funder, by devising a commissioning brief, the HTA programme specified the research question and study design. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The HTA editors and publisher have tried to ensure the accuracy of the authors' report and would like to thank the referees for their constructive comments on the draft document. However, they do not accept liability for damages or losses arising from material published in this report.
The views expressed in this publication are those of the authors and not necessarily those of the HTA programme or the Department of Health.
- NLM CatalogRelated NLM Catalog Entries
- Review Systematic review and modelling of the cost-effectiveness of cardiac magnetic resonance imaging compared with current existing testing pathways in ischaemic cardiomyopathy.[Health Technol Assess. 2014]Review Systematic review and modelling of the cost-effectiveness of cardiac magnetic resonance imaging compared with current existing testing pathways in ischaemic cardiomyopathy.Campbell F, Thokala P, Uttley LC, Sutton A, Sutton AJ, Al-Mohammad A, Thomas SM. Health Technol Assess. 2014 Sep; 18(59):1-120.
- Review Clinical effectiveness and cost-effectiveness of second- and third-generation left ventricular assist devices as either bridge to transplant or alternative to transplant for adults eligible for heart transplantation: systematic review and cost-effectiveness model.[Health Technol Assess. 2013]Review Clinical effectiveness and cost-effectiveness of second- and third-generation left ventricular assist devices as either bridge to transplant or alternative to transplant for adults eligible for heart transplantation: systematic review and cost-effectiveness model.Sutcliffe P, Connock M, Pulikottil-Jacob R, Kandala NB, Suri G, Gurung T, Grove A, Shyangdan D, Briscoe S, Maheswaran H, et al. Health Technol Assess. 2013 Nov; 17(53):1-499, v-vi.
- Review Elucigene FH20 and LIPOchip for the diagnosis of familial hypercholesterolaemia: a systematic review and economic evaluation.[Health Technol Assess. 2012]Review Elucigene FH20 and LIPOchip for the diagnosis of familial hypercholesterolaemia: a systematic review and economic evaluation.Sharma P, Boyers D, Boachie C, Stewart F, Miedzybrodzka Z, Simpson W, Kilonzo M, McNamee P, Mowatt G. Health Technol Assess. 2012; 16(17):1-266.
- Review Diagnostic management strategies for adults and children with minor head injury: a systematic review and an economic evaluation.[Health Technol Assess. 2011]Review Diagnostic management strategies for adults and children with minor head injury: a systematic review and an economic evaluation.Pandor A, Goodacre S, Harnan S, Holmes M, Pickering A, Fitzgerald P, Rees A, Stevenson M. Health Technol Assess. 2011 Aug; 15(27):1-202.
- Review The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of Technology Appraisal No. 111): a systematic review and economic model.[Health Technol Assess. 2012]Review The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of Technology Appraisal No. 111): a systematic review and economic model.Bond M, Rogers G, Peters J, Anderson R, Hoyle M, Miners A, Moxham T, Davis S, Thokala P, Wailoo A, et al. Health Technol Assess. 2012; 16(21):1-470.
- Growth Monitoring for Short Stature: Update of a Systematic Review and Economic ...Growth Monitoring for Short Stature: Update of a Systematic Review and Economic Model
- The Age of BLood Evaluation (ABLE) randomised controlled trial: description of t...The Age of BLood Evaluation (ABLE) randomised controlled trial: description of the UK-funded arm of the international trial, the UK cost–utility analysis and secondary analyses exploring factors associated with health-related quality of life and health-care costs during the 12-month follow-up
Your browsing activity is empty.
Activity recording is turned off.
See more...